At what pace is the tildrakizumab market growing, and what is its estimated value?
The tildrakizumab market size has grown rapidly in recent years. It will grow from $1.57 billion in 2024 to $1.76 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to the rise in the demand for the psoriasis treatment, rise in psoriasis prevalence, high prevalence of alcohol and smoking consumption, increase in research and development activities, increase in healthcare expenditure.
The tildrakizumab market size is expected to see rapid growth in the next few years. It will grow to $2.75 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to growing prevalence of psoriasis, the rising initiative, rising prevalence of plaque psoriasis and psoriatic arthritis, growing awareness and education, high prevalence of alcohol and smoking consumption. Major trends in the forecast period include product innovations, combination therapies, shift toward biologic and targeted therapies, new injectable drugs, shift towards personalized medicine.
Get Your Free Sample of The Global Tildrakizumab Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21301&type=smp
What are the top drivers to the rising demand in the tildrakizumab market?
The growing prevalence of psoriasis is expected to propel the growth of the tildrakizumab market going forward. Psoriasis is a chronic autoimmune condition that causes rapid skin cell turnover, leading to red, scaly patches on the skin. The growing prevalence of psoriasis is attributed to genetic predisposition, immune system dysfunction, environmental triggers, and lifestyle factors such as stress, smoking, and obesity. Tildrakizumab treats psoriasis by specifically inhibiting interleukin-23 (IL-23), a cytokine that triggers excessive skin cell growth and inflammation, helping to reduce plaques, scaling, and redness. For instance, in May 2024, according to the National Center for Biotechnology Information, a US-based national library of medicine, in 2022, the prevalence of PsA was 0.221%, with an incidence rate of 13.54 per 100,000 population. This prevalence has tripled compared to previous estimates. Therefore, the growing prevalence of psoriasis is driving the growth of the tildrakizumab market.
Improvement In Healthcare Facilities Drives Growth Of The Market
The improvement of healthcare facilities is expected to propel the growth of the tildrakizumab market going forward. Healthcare facilities are establishments that offer medical care and services, such as hospitals, clinics, and diagnostic centers, to treat and support patients. Healthcare facilities are improving due to several factors such as increased investment in healthcare infrastructure, a focus on patient-centered care, population growth, and aging. Enhancing healthcare facilities improves patient access to advanced biologic treatments, streamlines diagnosis and specialist referrals, ensures better cold chain management for biologics, and expands healthcare provider awareness, all of which collectively support the adoption and efficacy of tildrakizumab in treating chronic inflammatory conditions such as psoriasis. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals, representing a 0.591% increase from the previous year when there were 6,093 hospitals. Therefore, the improvement of healthcare facilities is driving the growth of the tildrakizumab market.
How is the tildrakizumab market segmented?
The tildrakizumab market covered in this report is segmented –
1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Other Indications
2) By Dosage Form: Injectable, Oral
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End-User: Hospitals, Specialty Clinics, Homecare
Subsegments:
1) By Plaque Psoriasis: Moderate Plaque Psoriasis, Severe Plaque Psoriasis, Treatment-Resistant Plaque Psoriasis
2) By Psoriatic Arthritis: Peripheral Psoriatic Arthritis, Axial Psoriatic Arthritis, Enthesitis-related Psoriatic Arthritis
3) By Other Indications: Inflammatory Skin Disorders, Off-Label Autoimmune Conditions, Emerging Therapeutic Applications
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/tildrakizumab-global-market-report
Who are the top competitors in the tildrakizumab market?
Major companies operating in the tildrakizumab market are Sun Pharmaceutical Industries Ltd., Almirall S.A.
What significant trends should we anticipate in the tildrakizumab market over the forecast period?
Major companies operating in the tildrakizumab market are focusing on development of innovative formulations such as monoclonal antibody injection to enhance treatment efficacy and improve patient outcomes. Monoclonal antibody injection refers to the administration of laboratory-produced antibodies designed to target specific antigens in the body for therapeutic or preventive purposes. For instance, in May 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, received approval from the Chinese health authority, National Medical Products Administration (NMPA), for tildrakizumab injection used in treatment of plaque psoriasis. It works by targeting interleukin-23 (IL-23), a cytokine involved in the inflammatory response that causes psoriasis. IL-23, tildrakizumab helps reduce inflammation and slow down excessive skin cell growth, improving symptoms such as redness, scaling, and plaque formation.
Which regional trends are influencing the tildrakizumab market, and which area dominates the industry?
North America was the largest region in the tildrakizumab market in 2024. Asia-Pacific expected to be the fastest-growing region in the forecast period. The regions covered in the tildrakizumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Tildrakizumab Market Report 2025 Offer?
The tildrakizumab market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Tildrakizumab is a humanized monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23), blocking its interaction with the IL-23 receptor. This inhibition prevents downstream inflammatory signaling, reducing the activation of pro-inflammatory cytokines and immune cells involved in autoimmune conditions such as plaque psoriasis.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21301
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
